SELLAS Life Sciences Group Inc. (SLS) shares climbed 5.77% in the after-market on Friday, May 28, 2021, and closed the week at $12.65 per share. in Friday’s morning session, SLS’s stock gained 11.57% to close Friday’s normal session at $11.96 per share. SLS shares have risen 248.69% over the last 12 months, and they have moved up 22.67% in the past week. Over the past three months, the stock has jumped 41.71%, while over the past six months, it has soared 236.90%.
Upcoming Shareholder Update Call
SELLAS Life Sciences Group, Inc will host a Shareholder Update Call on Thursday, June 3, 2021, at 8:30 a.m. ET.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
The call will be facilitated by SELLAS’ President & CEO, Angelos Stergiou, MD, ScD. h.c., who will provide a corporate update.
Read More
New Patent granted for Galinpepimut-S
OnMay 27, 2021,U.S. Patent and Trademark Office (USPTO) has issued a Notice of Allowance in a patent application covering the use of galinpepimut-S (GPS), the SELLAS Life Sciences Group Wilms Tumor-1 (WT1)-targeting peptide immunotherapeutic, in combination with checkpoint inhibitor therapies for the treatment of WT1-expressing cancers.
Financial results announcement
On May 13, 2021, SELLAS Life Sciences Group, Inc. released its financial results for the quarter ended March 31, 2021.
Q1 2021 financial highlights
- SELLAS Life Sciences Group recorded $5.7 million of licensing revenue in Q1 2021 compared to zero revenue in Q1 2020.
- Research and development expenses were $4.3 million in Q1 2021 compared to $1.9 million for the first quarter of 2020.
- Total operating expenses were $7.95 million in Q1 2021 compared to $4.06 million in Q1 2020.
- Net loss attributable to common stockholders was $2.4 million or a basic and diluted loss per share attributable to common stockholders of $0.16 in Q1 2021 compared to a net loss attributable to common stockholders of $4.2 million or a basic and diluted loss per share attributable to common stockholders of $0.66for the first quarter of 2020.
- SELLAS Life Sciences Group had cash and cash equivalents totalled approximately $28 million on March 31, 2021.
FY-2020 financial results announcement
On March 23, 2021, SELLAS Life Sciences Group, Inc released its financial results for the full year ended December 31, 2020.
FY-2020 financial highlights
- SELLAS Life Sciences Group earned a licensing revenue of $1.9 million in FY 2020 compared to zero revenue in FY 2019.
- Research and development expenses were $9.3 million in FY 2020 compared to $7.3 million in FY 2019.
- General and administrative expenses were $9.6 million in FY 2020 compared to $9.9 million for the year December 31, 2019.
- Net loss attributable to common stockholders was $16.8 million or a basic and diluted loss per share of $2.11 in FY 2020, compared to a net loss attributable to common stockholders of $28.0 million or a basic and diluted loss per share of $10.92 in FY 2019.
- As of December 31, 2020, SELLAS had cash and cash equivalents totalled approximately $35.3 million December 31, 2020.
Conclusion
The new patent approval could be the reason behind SLS exceptional performance on Friday and we expect SLS stock to continue its momentum after the long weekend as well.
